Published in Eur J Cancer on January 04, 2010
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer | NCT02549534
Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol (2010) 1.71
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol (2012) 1.57
Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res (2013) 1.33
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res (2014) 1.17
Cancer-treatment-induced neurotoxicity-focus on newer treatments. Nat Rev Clin Oncol (2015) 1.08
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol (2013) 1.05
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy. Cancer Chemother Pharmacol (2013) 1.03
Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. PLoS One (2015) 1.02
Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox Biol (2014) 0.99
Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer (2012) 0.98
Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol (2015) 0.97
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst (2014) 0.94
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol (2015) 0.94
Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol (2015) 0.91
Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol (2011) 0.83
Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity? Oncologist (2011) 0.80
Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review. Crit Rev Oncol Hematol (2015) 0.80
Bortezomib-induced painful neuropathy in patients with multiple myeloma. Contemp Oncol (Pozn) (2013) 0.79
Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab. Jpn Clin Med (2014) 0.79
Assessment of chemotherapy-induced peripheral neuropathy using the LDIFLARE technique: a novel technique to detect neural small fiber dysfunction. Brain Behav (2015) 0.78
Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study. Support Care Cancer (2015) 0.78
Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst (2015) 0.76
Vitamin E for preventing chemotherapy-induced peripheral neuropathy. Support Care Cancer (2011) 0.76
Comment on: 'Subgroup effects in a randomized trial of different types and doses of exercise during breast cancer chemotherapy'. Br J Cancer (2014) 0.75
Neurotoxicity associated with cancer therapy. J Adv Pract Oncol (2012) 0.75
Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology. ESMO Open (2016) 0.75
Tracking Epidermal Nerve Fiber Changes in Asian Macaques: Tools and Techniques for Quantitative Assessment. Toxicol Pathol (2016) 0.75
Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device. Cancer Sci (2016) 0.75
Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Support Care Cancer (2015) 0.75
Paclitaxel causes degeneration of both central and peripheral axon branches of dorsal root ganglia in mice. BMC Neurosci (2016) 0.75
A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises. Exp Hematol Oncol (2017) 0.75
NON-INVASIVE EVALUATION OF NERVE CONDUCTION IN SMALL DIAMETER FIBERS IN THE RAT. Physiol J (2013) 0.75
Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res (2016) 0.75
Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy. Support Care Cancer (2017) 0.75
Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support Care Cancer (2017) 0.75
Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol (2013) 2.29
Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res (2005) 2.11
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst (2007) 2.01
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol (2006) 1.66
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry (2013) 1.55
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension (2011) 1.54
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer (2004) 1.31
Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res (2008) 1.19
Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res (2008) 1.16
Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget (2011) 1.14
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res (2004) 1.13
Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer (2005) 1.11
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol (2011) 1.11
Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer (2012) 1.08
New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies. Cancer Res (2006) 1.04
Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. Brain (2004) 1.00
Chemotherapy-induced neuropathy. Curr Treat Options Neurol (2011) 0.99
Learning disorders in epilepsy. Epilepsia (2006) 0.99
CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res (2004) 0.98
Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother (2007) 0.96
Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst (2011) 0.95
Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. J Thorac Oncol (2007) 0.89
Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res (2006) 0.88
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. J Thorac Oncol (2015) 0.86
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst (2008) 0.86
Case report of synchronous multicentric osteosarcoma and review of the literature: the importance of autopsy for diagnosis. Tumori (2005) 0.85
Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. J Gene Med (2005) 0.85
A review of the costs of managing childhood epilepsy. Pharmacoeconomics (2005) 0.85
Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma. Biomed Res Int (2013) 0.85
Mitochondrial dysfunction due to mutant copper/zinc superoxide dismutase associated with amyotrophic lateral sclerosis is reversed by N-acetylcysteine. Neurobiol Dis (2003) 0.84
Comment on: "Is there a role for vitamin D in human reproduction?" Horm Mol Biol Clin Investig (2016) 0.84
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC). Am J Clin Oncol (2003) 0.82
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemother Pharmacol (2012) 0.82
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. J Cancer Res Clin Oncol (2014) 0.81
TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy. Neurol Sci (2014) 0.80
Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity? Oncologist (2011) 0.80
Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment. Mol Cancer Ther (2007) 0.80
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst (2014) 0.79
c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome. Endocr Relat Cancer (2009) 0.79
Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate. Anticancer Res (2003) 0.79
Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev (2004) 0.79
Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget (2015) 0.79
A panel of macroautophagy markers in lymphomonocytes of patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2011) 0.79
Pulmonary carcinoid tumours: indolent but not benign. Oncology (2008) 0.78
Lack of evidence for oxidative stress in sporadic amyotrophic lateral sclerosis fibroblasts. Neurodegener Dis (2008) 0.78
Impairment of glutamate transport and increased vulnerability to oxidative stress in neuroblastoma SH-SY5Y cells expressing a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis. Neurochem Int (2004) 0.78
Oxaliplatin doublets in non-small cell lung cancer: a literature review. Lung Cancer (2008) 0.78
First report of PSEN2 mutation presenting as posterior cortical atrophy. Alzheimer Dis Assoc Disord (2015) 0.78
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer (2010) 0.77
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. J Peripher Nerv Syst (2014) 0.77
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. Biomed Pharmacother (2004) 0.76
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool: an observational study. Medicine (Baltimore) (2015) 0.76
Isolated cardiac metastasis from squamous cell esophageal cancer. Tumori (2015) 0.76
Generalized action myoclonus associated with escitalopram in a patient with mixed dementia. J Clin Psychopharmacol (2011) 0.75
Primitive reflexes in amyotrophic lateral sclerosis: prevalence and correlates. J Neurol (2014) 0.75
Maintenance therapy in NSCLC: why? To whom? Which agent? J Exp Clin Cancer Res (2011) 0.75
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. Neurology (2017) 0.75
Diaphragm ultrasonography in the management of patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 0.75
Integrated therapeutic strategies for anaplastic thyroid carcinoma. Tumori (2004) 0.75
Neurophysiological examination of dorsal sural nerve. Muscle Nerve (2012) 0.75
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue. Pain Manag (2013) 0.75
Behavioural But Not Cognitive Impairment Is a Determinant of Caregiver Burden in Amyotrophic Lateral Sclerosis. Eur Neurol (2016) 0.75
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer. Lung Cancer (2004) 0.75
Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. Oncology (2004) 0.75
Muscle ultrasonography for detecting fasciculations in frontotemporal dementia. Amyotroph Lateral Scler Frontotemporal Degener (2014) 0.75
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer (2016) 0.75
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? J Thorac Oncol (2008) 0.75